Spots Global Cancer Trial Database for antiangiogenesis
Every month we try and update this database with for antiangiogenesis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | NCT03577743 | Metastatic Trip... Safety Issues Efficacy | Bevacizumab | 18 Years - 75 Years | Assiut University | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | NCT00093873 | Tumors | Anti-angiogenes... AMG 706 | 18 Years - | Amgen | |
| Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | NCT00078390 | Non Small Cell ... Lung Cancer Stage IIIA Non ... Stage IIIB Non ... | S-3304 Chemo-irradiati... | 18 Years - 85 Years | Shionogi Inc. | |
| A Phase 1 Study of S-3304 in Patients With Solid Tumors | NCT00033215 | Solid Tumors | S-3304 | 18 Years - 85 Years | Shionogi Inc. | |
| PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT05341193 | Nasopharyngeal ... | Bevacizumab+Tor... Bevacizumab+Tor... | 18 Years - 65 Years | Sun Yat-sen University | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | NCT00942877 | Sarcoma, Alveol... | AZD2171 | - 16 Years | National Institutes of Health Clinical Center (CC) | |
| PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT05341193 | Nasopharyngeal ... | Bevacizumab+Tor... Bevacizumab+Tor... | 18 Years - 65 Years | Sun Yat-sen University | |
| Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer | NCT00367679 | Non-Small Cell ... Lung Cancer, No... | Pazopanib | 21 Years - | GlaxoSmithKline | |
| Bevacizumab and Irinotecan to Treat Brain Tumors | NCT00393094 | High-Grade Glio... | Bevacizumab Irinotecan hydr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | NCT00093873 | Tumors | Anti-angiogenes... AMG 706 | 18 Years - | Amgen | |
| Dose-Escalation and Safety Trial of YN968D1 | NCT01497704 | Cancer Patients... | YN968D1 | 18 Years - | Elevar Therapeutics | |
| Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor | NCT01260025 | Tolerability Pharmacokinetic... Endostatin | PEDylated Recom... | 18 Years - 65 Years | Sun Yat-sen University | |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | NCT03577743 | Metastatic Trip... Safety Issues Efficacy | Bevacizumab | 18 Years - 75 Years | Assiut University | |
| AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia | NCT00321581 | Refractory or R... Acute Myelogeno... | Cediranib, AZD2... | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose-Escalation and Safety Trial of YN968D1 | NCT01497704 | Cancer Patients... | YN968D1 | 18 Years - | Elevar Therapeutics | |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | NCT00995007 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | ZD6474 (Vandeta... Carboplatin | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Dose-Escalation and Safety Trial of YN968D1 | NCT01497704 | Cancer Patients... | YN968D1 | 18 Years - | Elevar Therapeutics | |
| Bevacizumab and Irinotecan to Treat Brain Tumors | NCT00393094 | High-Grade Glio... | Bevacizumab Irinotecan hydr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer | NCT03042611 | Gastric Cancer Gastric Adenoca... | Rivoceranib Placebo | 18 Years - | Elevar Therapeutics | |
| Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor | NCT01260025 | Tolerability Pharmacokinetic... Endostatin | PEDylated Recom... | 18 Years - 65 Years | Sun Yat-sen University | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM) | NCT04952571 | Recurrent Gliob... | Camrelizumab an... | 18 Years - 70 Years | Beijing Sanbo Brain Hospital | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor | NCT00262327 | Advanced Solid ... | Antangiogenesis endostatin gene | 18 Years - 65 Years | Sun Yat-sen University | |
| Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | NCT00094107 | Melanoma Skin Neoplasms | Axitinib [AG-01... | 18 Years - | Pfizer | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
